Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
T47D | Vorinostat | HDAC | Misc | 1.8007 | -0.1567 | 0.1750 | 0.0409 | 2.2684 | 2.0704 | 0.99157 |
T47D | Luminespib | HSP90 | Misc | 0.0060689 | 0.0212 | 0.5165 | 0.0278 | 4.3267 | 0.0059347 | 0.99479 |
T47D | A-1210477 | Mcl-1 | Misc | Inf | 0.5752 | 0.0227 | 0.0055 | 5.0000 | 3.7781 | 0.96287 |
T47D | Olaparib | PARP | Misc | Inf | 0.5304 | 0.0302 | 0.0015 | 4.9632 | 3.5388 | 0.95841 |
T47D | Bleomycin | Radiation | Misc | 0.19877 | -0.0840 | 0.4615 | 0.0190 | 0.9701 | 0.24632 | 0.9812 |
T47D | Ipatasertib | AKT | PI3K/mTOR | 0.13653 | 0.1331 | 0.4303 | 0.0112 | 1.0853 | 0.10541 | 0.99474 |
T47D | Alpelisib | PI3Ka | PI3K/mTOR | 0.15284 | -0.0332 | 0.4568 | 0.0181 | 0.7816 | 0.17573 | 0.98947 |
T47D | Taselisib | PI3Ka, g, d | PI3K/mTOR | 0.0017858 | -0.1047 | 0.8990 | 0.0550 | 1.1740 | 0.0018197 | 0.97255 |
T47D | TGX221 | PI3Kb | PI3K/mTOR | Inf | 0.7986 | -0.0066 | -0.0002 | 2.2233 | 4.3807 | 0.7868 |
T47D | Torin2 | mTOR/ATM/ATR | PI3K/mTOR | 0.0060179 | 0.0099 | 0.5239 | 0.0218 | 1.4244 | 0.0056296 | 0.99382 |
T47D | Everolimus | mTOR1 | PI3K/mTOR | -Inf | 0.2975 | 0.6157 | 0.0150 | 0.1000 | 5.9599e-07 | 0.77906 |
T47D | INK-128 | mTORC1/2 | PI3K/mTOR | 0.0052554 | -0.0486 | 0.6885 | 0.0237 | 1.4713 | 0.0052599 | 0.99662 |
T47D | PF-4708671 | p70S6K | PI3K/mTOR | 3.7629 | 0.3659 | 0.1275 | 0.0024 | 1.0704 | 1.8083 | 0.98136 |
T47D | Buparlisib | pan PI3K | PI3K/mTOR | 0.24826 | -0.4183 | 0.4821 | 0.0867 | 0.7426 | 0.73229 | 0.99516 |
T47D | Pictilisib | pan PI3K | PI3K/mTOR | 0.15529 | -0.1470 | 0.4772 | 0.0336 | 0.7031 | 0.2394 | 0.99267 |
T47D | Ceritinib | ALK | RTK | 1.5629 | -0.8550 | 0.3123 | 0.1208 | 1.6029 | 3.1015 | 0.97809 |
T47D | Neratinib | EGFR/HER2 | RTK | 0.42314 | 0.1949 | 0.2741 | 0.0059 | 0.4966 | 0.81232 | 0.9874 |
T47D | Tivantinib | MET | RTK | 0.3478 | -0.1544 | 0.3824 | 0.1267 | 3.7033 | 0.37139 | 0.99567 |
T47D | Cediranib | VEGFR/cKIT | RTK | 4.1027 | -0.6403 | 0.1246 | 0.0754 | 2.9281 | 5.9706 | 0.99504 |
T47D | Cabozantinib | VEGFR2/MET | RTK | 7.8808 | 0.3126 | 0.0578 | 0.0045 | 1.8911 | 14.0627 | 0.99417 |
CAMA-1 | Abemaciclib | CDK4/6 | Cell cycle | 0.007859 | 0.2222 | 0.6130 | -0.0040 | 1.3608 | 0.0046978 | 0.97968 |
CAMA-1 | Palbociclib | CDK4/6 | Cell cycle | 0.074216 | 0.2816 | 0.3530 | -0.0016 | 1.1861 | 0.038743 | 0.99185 |
CAMA-1 | AZD7762 | CHK1/2 | Cell cycle | 0.25282 | -0.0865 | 0.4185 | 0.0673 | 1.0859 | 0.30852 | 0.99437 |
CAMA-1 | Volasertib | PLK | Cell cycle | 0.0078167 | -0.2965 | 0.6740 | 0.2054 | 3.0791 | 0.009001 | 0.98295 |
CAMA-1 | Dinaciclib | pan CDK | Cell cycle | 0.014558 | -0.4849 | 0.6062 | 0.1927 | 2.0283 | 0.019954 | 0.99839 |